DexCom Statistics
Share Statistics
DexCom has 390.60M shares outstanding. The number of shares has increased by 1.32% in one year.
| Shares Outstanding | 390.60M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -2.53% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 385.65M |
| Failed to Deliver (FTD) Shares | 9.23K |
| FTD / Avg. Volume | 0.23% |
Short Selling Information
The latest short interest is 9.33M, so 2.39% of the outstanding shares have been sold short.
| Short Interest | 9.33M |
| Short % of Shares Out | 2.39% |
| Short % of Float | 2.42% |
| Short Ratio (days to cover) | 2.62 |
Valuation Ratios
The PE ratio is 88.46 and the forward PE ratio is 36.62. DexCom 's PEG ratio is 1.08.
| PE Ratio | 88.46 |
| Forward PE | 36.62 |
| PS Ratio | 13.22 |
| Forward PS | 5.8 |
| PB Ratio | 23.16 |
| P/FCF Ratio | 93.57 |
| PEG Ratio | 1.08 |
Enterprise Valuation
DexCom Inc. has an Enterprise Value (EV) of 49.93B.
| EV / Earnings | 92.2 |
| EV / Sales | 13.78 |
| EV / EBITDA | 54.46 |
| EV / EBIT | 83.53 |
| EV / FCF | 97.53 |
Financial Position
The company has a current ratio of 2.84, with a Debt / Equity ratio of 1.18.
| Current Ratio | 2.84 |
| Quick Ratio | 2.48 |
| Debt / Equity | 1.18 |
| Total Debt / Capitalization | 54.06 |
| Cash Flow / Debt | 0.31 |
| Interest Coverage | 29.44 |
Financial Efficiency
Return on equity (ROE) is 0.26% and return on capital (ROIC) is 9.77%.
| Return on Equity (ROE) | 0.26% |
| Return on Assets (ROA) | 0.09% |
| Return on Capital (ROIC) | 9.77% |
| Revenue Per Employee | 381.29K |
| Profits Per Employee | 57.00K |
| Employee Count | 9.50K |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.38 |
Taxes
| Income Tax | 168.90M |
| Effective Tax Rate | 0.24 |
Stock Price Statistics
The stock price has increased by -38.52% in the last 52 weeks. The beta is 1.17, so DexCom 's price volatility has been higher than the market average.
| Beta | 1.17 |
| 52-Week Price Change | -38.52% |
| 50-Day Moving Average | 75.96 |
| 200-Day Moving Average | 95.11 |
| Relative Strength Index (RSI) | 55.42 |
| Average Volume (20 Days) | 3.95M |
Income Statement
In the last 12 months, DexCom had revenue of 3.62B and earned 541.50M in profits. Earnings per share was 1.44.
| Revenue | 3.62B |
| Gross Profit | 2.29B |
| Operating Income | 597.70M |
| Net Income | 541.50M |
| EBITDA | 916.70M |
| EBIT | 597.70M |
| Earnings Per Share (EPS) | 1.44 |
Balance Sheet
The company has 566.30M in cash and 2.59B in debt, giving a net cash position of -2.03B.
| Cash & Cash Equivalents | 566.30M |
| Total Debt | 2.59B |
| Net Cash | -2.03B |
| Retained Earnings | 1.02B |
| Total Assets | 6.35B |
| Working Capital | 2.53B |
Cash Flow
In the last 12 months, operating cash flow was 748.50M and capital expenditures -236.60M, giving a free cash flow of 511.90M.
| Operating Cash Flow | 748.50M |
| Capital Expenditures | -236.60M |
| Free Cash Flow | 511.90M |
| FCF Per Share | 1.33 |
Margins
Gross margin is 6.32K%, with operating and profit margins of 1.65K% and 1.50K%.
| Gross Margin | 6.32K% |
| Operating Margin | 1.65K% |
| Pretax Margin | 1.96K% |
| Profit Margin | 1.50K% |
| EBITDA Margin | 25.31% |
| EBIT Margin | 16.5% |
| FCF Margin | 14.13% |
Dividends & Yields
DXCM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 1.81% |
| FCF Yield | 1.64% |
Analyst Forecast
The average price target for DXCM is $95, which is 19.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $95 |
| Price Target Difference | 19.2% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
Stock Splits
The last stock split was on Jun 13, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Jun 13, 2022 |
| Split Type | forward |
| Split Ratio | 4:1 |
Scores
| Altman Z-Score | 6.11 |
| Piotroski F-Score | 5 |